Contact
THE SCIENCE
OF EARLIER
Transforming the early detection
and intervention of cancer
Our Unique Biomarker
Technology
OncAlert Labs develops tests based on patented technology that detects specific protein markers known to indicate an elevated risk for early stage cancers, even prior to observation of visual or physical symptoms.
Actionable Insights for Earlier Oral Cancer
Detection
OraMark’s oral rinse collection method is easy to administer and non-invasive for the patient. The test delivers accurate, quantitative results that help optimize patient management and surveillance both pre- and post-biopsy.
Featured News and Events
Jul 28, 2016 | Miami Herald
Head, neck cancer’s global challenge
Head and neck cancer is a growing challenge with more than 650,000 new cases and more than 360,000 deaths worldwide each year. Historically, the death rate associated with this cancer is particularly high due to late-stage diagnosis and intervention. More than 40 percent of those diagnosed with oral cancer die within five years.
Jul 22, 2016 | Medical Laboratory Observer
Special Feature: Saliva as a diagnostic tool
By Elizabeth Franzmann, MD, July 2015 Salivary diagnostics holds tremendous potential for the diagnosis, prognosis, and monitoring of cancer.1 The specimen can be obtained simply, inexpensively, and less invasively than blood and thus can be collected without special training.
Jul 13, 2016 |
Vigilant Biosciences Announces Oral Presentation on CD44 and Associated Markers in Oral Rinses and Tissues from Oral Cancer Patients at AHNS 9th International Conference on Head and Neck Cancer
Company to give presentation of data related to proof-of-concept studies by Sylvester Comprehensive Cancer Center (“Sylvester”) at the University of Miami Miller School of Medicine, titled CD44 and Associated Markers in Oral Rinses and Tissues from Oral Cancer Patients at American Head and Neck Society (AHNS) 9th International Conference on Head and Neck Cancer.